Observation: In my RSL3-induced ferroptosis mouse model, no significant reduction in GPX4 protein levels was observed under certain treatment conditions.
Experimental Details:
Notable Finding: Only the acute treatment (single high-dose RSL3, 24-hour endpoint) resulted in a modest decrease in GPX4 expression, whereas prolonged administration (3–6 days) did not significantly alter GPX4 levels.
Question: What could explain the absence of GPX4 suppression in the chronic RSL3 treatment group despite its established role in ferroptosis induction?